

☐ The enclosed document is being transmitted via facsimile.



COPY OF PAPERS
ORIGINALLY FILED

PATENT

Attorney Docket No. 0459-0461P

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 22 2002

TECH CENTER 1600/2900

APPLICANTS: WEIDNER, M. CONF: 9245
SERIAL NO.: 09/613,468 GROUP: 1616
FILED: July 10, 2000 EXAMINER: GOLLAMUDI, S.
FOR: NOVEL COMPOSITION CONTAINING EXTRACTS OF
BUTYROSPERMUM PARKII AND THE USE OF SUCH A
COMPOSITION FOR PREPARING A MEDICAMENT OR A DIETARY
SUPPLEMENT FOR THE TREATMENT OR PREVENTION OF
INFLAMMATORY HYPERSENSITIVITY OR PAIN

RESPONSE TO OFFICE ACTION

Assistant Commissioner for Patents
Washington, D.C. 20231

August 12, 2002

Sir:

In response to the Examiner's Office Action dated February 12, 2002, the period for response having been extended three (3) months to August 12, 2002, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

38/21/2002 SZEWDTEI 00000031 09613468

01 FC:253 72.00 DP
02 FC:217 460.00 DP

AMENDMENTS

Please amend the claims as follows:

C2 1 (Amended). A pharmaceutical composition or a dietary supplement comprising an extract or concentrate of Butyrospermum parkii comprising at least 5% (w/w) of a Butyrospermum-triterpene

fraction such that said composition comprises at least 5 % w/w of said Butyrospermum-triterpene fraction,

said Butyrospermum-triterpene fraction comprising:

- CA
- at least 2% (w/w) lupeol;
 - at least 2% (w/w) α -amyrin and/or β -amyrin; and
 - at least 2% (w/w) butyrospermol;

wherein said triterpenes may be in the form of free alcohols or esters thereof.

2. (Amended) The pharmaceutical composition or a dietary supplement according to claim 1, wherein said Butyrospermum-triterpene fraction comprises:

- 10-40% (w/w) lupeol;
- 10-40% (w/w) α -amyrin and/or β -amyrin;
- 10-40% (w/w) butyrospermol.

3. (Amended) The pharmaceutical composition or dietary supplement according to claim 1, wherein the extract or concentrate of Butyrospermum parkii further comprises a sterol fraction comprising at least one sterol selected from the group consisting of stigmasterol, avanasterol, 24-methyl-cholest-7-enol, karitesterol A, karitesterol B and α -spinasterol, wherein said sterols may be in the form of free alcohols or esters thereof.

4 (Amended). The pharmaceutical composition or dietary supplement according to claim 1, wherein the Butyrospermum-triterpene fraction comprises up to 100% (w/w) of the extract or concentrate of Butyrospermum parkii.

5. (Amended) The pharmaceutical composition or dietary supplement according to claim 3, wherein the ratio between the Butyrospermum-triterpene fraction and the sterol fraction is in the range of 1:100 to 500:1 (w/w).

6. (Amended) The pharmaceutical composition or dietary supplement according to claim 1, further comprising an extract of Calendula officinalis.

7. (Amended) The pharmaceutical composition according to claim 1 formulated for systemic administration.

8. (Amended) The pharmaceutical composition according to claim 1 formulated for topical administration.